Perinatal Stem Cell Society 2018 annual conference
The 4th annual International Perinatal Stem Cell Society conference is taking place March 1-2, 2018 in Salt Lake City, Utah. The conference will be held at The Leonardo Museum, a perfect venue for a meeting which is expected to host between 200 and 250 attendees.
The world class faculty that are confirmed as speakers makes this meeting a must attend event for all members of the regenerative medicine field. For those who want to learn more about novel applications of cord blood or perinatal “361” tissue products, this event should not be missed.
The conference agenda is full of amazing speakers, but here are a few highlights:
C. Randal Mills, PhD
Chief Executive Officer of the National Marrow Donor Program
How the NMDP plans to save more lives with cellular therapy
Joanne Kurtzberg, MD
Director Pediatric Blood and Marrow Transplant Program at Duke University
Novel applications of cord blood derived therapies for genetic and acquired brain diseases.
Timothy J. Nelson, MD, PhD
Faculty of Mayo Clinic College of Medicine
Autologous UCB to rebuild hearts for congenital heart disease.
Robert Hariri, MD, PhD
Co-Founder, Human Longevity Inc.
Stem cells and longevity: Placental stem cells as platform to correct age-related proteomic defects
Panel Discussion: What is an MSC?
Moderated by Sean Murphy, PhD, of Wake Forest University. Participants are: Arnold Caplan, PhD, of Case Western Reserve University; Joanne Kurtzberg, MD, of Duke University; Rouzbeh Taghizadeh, PhD, of AuxoCell Laboratories, Inc.; and Tim Ganey, PhD, of Vivex Biomedical
Each year the role of the Perinatal Stem Cell Society expands to follow more priorities in the field. This year, community members have expressed a desire to work together to set voluntary standards for all products derived from perinatal tissues. There are many serious companies in this field that treat patients legally under the FDA’s 361 regulations, and these companies want to ensure that only the highest quality products with the highest safety profile are ever administered to patients.
A cautionary example is set by recent news reports about adipose stem cell clinics. In that field, a few really bad actors caused the FDA to crack down on the entire field and in doing so ultimately caused harm to patients who would otherwise have benefited from quality adipose treatments. As an industry, the perinatal stem cell field must self-police and not allow the fringe cowboys to ruin the huge therapeutic opportunity that perinatal tissue and cellular products provide.
Community members will discuss these standards in person, and that discussion will be open to the public. Anyone interested in joining the official working group please contact Kyle Cetrulo.